These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 23337074)

  • 1. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review.
    Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM
    Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence.
    Gartlehner G; Hansen RA; Jonas BL; Thieda P; Lohr KN
    Clin Rheumatol; 2008 Jan; 27(1):67-76. PubMed ID: 17570009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs.
    Ungar WJ; Costa V; Hancock-Howard R; Feldman BM; Laxer RM
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):111-9. PubMed ID: 20740607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.
    Otten MH; Anink J; Spronk S; van Suijlekom-Smit LW
    Ann Rheum Dis; 2013 Nov; 72(11):1806-12. PubMed ID: 23172748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review.
    Diener C; Horneff G
    Expert Opin Drug Saf; 2019 Aug; 18(8):719-732. PubMed ID: 31204508
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
    Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
    Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
    Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
    Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
    Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
    Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].
    Minden K; Klotsche J; Niewerth M; Horneff G; Zink A
    Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
    McErlane F; Foster HE; Davies R; Lunt M; Watson KD; Symmons DP; Hyrich KL
    Rheumatology (Oxford); 2013 Oct; 52(10):1905-13. PubMed ID: 23873820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
    Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
    Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
    Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
    Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
    Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
    Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Windschall D; Horneff G
    Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.